Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Drug Regulator Softens Stand On Emergency Contraceptive Pills; Ad Campaigns On As Doctors Advise Caution

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Less than six months after the Drug Controller General of India clamped a ban over mass media advertisements of popular oral emergency contraceptive I-pill, the segment leader that changed hands from Cipla to Piramal Healthcare is aggressively back on national television channels with frequent time spots

You may also be interested in...



Boehringer Ingelheim Aims A Shot At India’s Booming OTC Market

The family-controlled German drug maker is preparing an entry into the Indian consumer health care segment, a market seeing a flurry of activity from its global competitors like GSK and Sanofi.

Boehringer Ingelheim Aims A Shot At India’s Booming OTC Market

The family-controlled German drug maker is preparing an entry into the Indian consumer health care segment, a market seeing a flurry of activity from its global competitors like GSK and Sanofi.

Indian Drug Regulators Closely Watch Ads On Oral Contraceptives - Is A Ban In The Offing Or Will The Doctor Decide?

MUMBAI - Controversial television advertisements on the use of emergency contraceptive pills marketed by companies like Cipla and Mankind Pharma is deepening the divide between pharmaceutical companies and Indian drug regulators

Related Content

UsernamePublicRestriction

Register

SC075203

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel